Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Ginkgo

I Asked ChatGPT’s Most Advanced Model to Find the Stocks Most Likely to 100x Over the Next 10 Years — Here’s What It Said

Here are the stocks that ChatGPT's most advanced model says are most likely to 100x over the next 10 years.

Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group

Why Ginkgo Bioworks Shares Are Rising After Announcement With Partner Cronos Group

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 7.63% to $2.68 after the company, and Cronos Group Inc (NASDAQ: CRON), announced the achievement of the third target productivity milestone in their par

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

The Daily Biotech Pulse: Veru Seeks Emergency Use Nod For COVID-19 Therapy, Vincerx Cuts Workforce, Moderna Starts Dosing In Flu Vaccine Study

Here's a roundup of top developments in the biotech space over the last 24 hours:

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

New 'hidden courtyard' to open along Stockport's Underbanks

"We want the yard to be an escape for visitors, where they can get a few minutes of headspace in a tranquil spot"

Manchester Evening News

Tesla Bull Cathie Wood Scoops Up $11.5M In Bill Gates-Backed Biotech's Stock

Ark Investment Management, led by Tesla Inc.

Elanco, Ginkgo Bioworks Launch BiomEdit, Microbiome-Focused Animal Health Firm

Elanco Animal Health Incorporated (NYSE:ELAN) and Ginkgo Bioworks Holdings Inc (NYSE:DNA) have launched BiomEdit, a microbiome innovation company. BiomEdit will discover, develop and introduce novel probiotics, bioactive molecules, engineered microbial medicines, and microbial monitoring services for animal health. In October last year, Elanco announced its intention to carve out its microbiome platform and pipeline under the leadership…

Here's Why Ginkgo Bioworks Shares Are Rising

Ginkgo Bioworks Holdings Inc (NYSE: DNA) shares are trading higher by 22.0% at $4.56 after the company reported better-than-expected fourth-quarter sales results and issued FY22 sales guidance above analyst estimates.

inkl

Read news from The Economist, FT, and more,
with one subscription

Ginkgo Bioworks Shares Gain As Q4 Sales, FY22 Guidance Surpass Street Expectations

Ginkgo Bioworks Shares Gain As Q4 Sales, FY22 Guidance Surpass Street Expectations

Ginkgo Bioworks Holdings Inc (NYSE: DNA) reported

Ginkgo Bioworks Adds Ultra-High-Throughput Screening Platform Via FGen Acquisition

Ginkgo Bioworks Adds Ultra-High-Throughput Screening Platform Via FGen Acquisition

Ginkgo Bioworks Holdings Inc (NYSE: DNA) has

Ginkgo Bioworks Announces Acquisition Of Massachusetts COVID-19 Testing Provider Project Beacon COVID-19 LLC; Terms Not Disclosed

Acquisition to enable Ginkgo to bolster its growing biosecurity platform and provide expanded COVID-19 testing options to communities in Massachusetts and beyond

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Ark Investment Management

Aehr Test Systems

Ginkgo Bioworks Holdings Inc

Ginkgo Bioworks

Cronos Group Inc

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play